# Shenzhen Ionova Life Sciences

Source: https://onco.cc/companies/shenzhen-ionova-life-sciences/  
OnCo record `shenzhen-ionova-life-sciences` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Shenzhen Ionova Life Sciences is a China-based biotechnology company running 3 late-stage cancer trials of INV-8989, INV-6452 and INV-9956 in colorectal cancer, non-small-cell lung cancer and pancreatic ductal adenocarcinoma.

## Summary

Shenzhen Ionova Life Sciences, based in Shenzhen, China, is a biotechnology company. Ionova Biosciences develops next-generation oncology therapeutics, aiming for new cancer treatments with clear clinical benefit and global competitiveness. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials, testing INV-8989, INV-6452 and INV-9956 in colorectal cancer, non-small-cell lung cancer, pancreatic ductal adenocarcinoma, ovarian cancer and endometrial cancer. The largest, NCT07612891 (A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumour), plans to enrol 201 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Shenzhen Ionova Life Sciences Co., Ltd.
- Tags: ctgov-sponsor
- HQ: Shenzhen
- Type: biotech
- Website: https://www.ionovabio.com

## Sources

- Official website: https://www.ionovabio.com
- ClinicalTrials.gov: trials led by Shenzhen Ionova Life Sciences: https://clinicaltrials.gov/search?lead=Shenzhen%20Ionova%20Life%20Sciences%20Co.%2C%20Ltd.

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- trials: [A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer](https://onco.cc/trials/nct06609005/), [A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor](https://onco.cc/trials/nct07612891/), [A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations](https://onco.cc/trials/nct07610798/)

---
JSON: https://onco.cc/api/v1/entities/shenzhen-ionova-life-sciences.json